Library / Laws / 118th Congress / Senate Bills / S. 2737
S. 2737
To require the Food and Drug Administration to determine whether to permit the use of enriched enrollment randomized withdrawal methodology with respect to clinical trials.
| Print stage | Date | Size | ⠃ |
|---|---|---|---|
| Introduced in Senate | 2023-09-07 | 2.9K | ⠃⠗⠋ |